Skip to main content
PMC home page
The AAPS Journal logoLink to The AAPS Journal
. 2006 Oct 6;8(4):E623–E631. doi: 10.1208/aapsj080471

Effect of physical state and particle size distribution on dissolution enhancement of nimodipine/PEG solid dispersions prepared by melt mixing and solvent evaporation

George Z Papageorgiou 5, Dimitrios Bikiaris 5,✉, Evagelos Karavas 1, Stavros Politis 1, Aristides Docoslis 2, Yong Park 2, Anagnostis Stergiou 3, Emmanouel Georgarakis 4
PMCID: PMC2751358  PMID: 17233527

Abstract

The physical structure and polymorphism of nimodipine were studied by means of micro-Raman, WAXD, DSC, and SEM for cases of the pure drug and its solid dispersions in PEG 4000, prepared by both the hot-melt and solvent evaporation methods. The dissolution rates of nimodipine/PEG 4000 solid dispersions were also measured and discussed in terms of their physicochemical characteristics. Micro-Raman and WAXD revealed a significant amorphous portion of the drug in the samples prepared by the hot-melt method, and that saturation resulted in local crystallization of nimodipine forming, almost exclusively, modification I crystals (racemic compound). On the other hand, mainly modification II crystals (conglomerate) were observed in the solid dispersions prepared by the solvent evaporation method. However, in general, both drug forms may appear in the solid dispersions. SEM and HSM microscopy studies indicated that the drug particle size increased with drug content. The dissolution rates were substantially improved for nimodipine from its solid dispersions compared with the pure drug or physical mixtures. Among solid dispersions, those resulting from solvent coevaporation exhibited a little faster drug release at drug concentrations lower than 20 wt%. Drug amorphization is the main reason for this behavior. At higher drug content the dissolution rates became lower compared with the samples from melt, due to the drug crystallization in modification II, which results in higher crystallinity and increased particle size. Overall, the best results were found for low drug content, for which lower drug crystallinity and smaller particle size were observed.

Keywords: nimodipine, solid dipersion, raman, polymorphism

Full Text

The Full Text of this article is available as a PDF (440.0 KB).

References

  • 1.Hörter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Res. 2001;46:75–87. doi: 10.1016/S0169-409X(00)00130-7. [DOI] [PubMed] [Google Scholar]
  • 2.Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47–60. doi: 10.1016/S0939-6411(00)00076-X. [DOI] [PubMed] [Google Scholar]
  • 3.Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231:131–144. doi: 10.1016/S0378-5173(01)00891-2. [DOI] [PubMed] [Google Scholar]
  • 4.Ford JL. The current status of solid dispersions. Pharm Acta Helv. 1986;61:69–88. [PubMed] [Google Scholar]
  • 5.Nakamichi K, Yasuura H, Kukui H, et al. New preparation method of solid dispersion by twin screw extruder. Pharm Technol Jpn. 1996;12:715–729. [Google Scholar]
  • 6.Breitenbach J, Berndl G, Neumann J, Rosenberg J, Simon D, Zeidler J. Solid dispersions by an integrated melt extrusion system. Proc Control Rel Soc. 1998;25:804–805. [Google Scholar]
  • 7.Meyer H, Bosset F, Vater W, Stoepel K, inventors. Pharmaceutical compositions containing unsymmetrical esters of 1,4=dihydropyridine 3,5-dicarboxylic acid. US Patent 3 932 645. January 13, 1976.
  • 8.Grunenberg A. Polymorphism and thermal analysis of pharmaceutical substances. Pharm Unserer Zeit. 1997;26:224–231. doi: 10.1002/pauz.19970260506. [DOI] [PubMed] [Google Scholar]
  • 9.Grunenberg A, Keil B, Heck JO. Polymorphism in binary mixtures, as exemplified by nimodipine. Int J Pharm. 1995;118:11–21. doi: 10.1016/0378-5173(94)00284-C. [DOI] [Google Scholar]
  • 10.Grunenberg A, Henck JO, Siesler HW. Theoretical derivation and practical application of energy/temperature diagrams as an instrument in preformulation studies of polymorphic drug substances. Int J Pharm. 1996;129:147–158. doi: 10.1016/0378-5173(95)04283-0. [DOI] [Google Scholar]
  • 11.European Pharmacopoeia. 5th ed. December 2005. Nimopidine Monograph: 3986.
  • 12.Cardoso TM, Rodrigues PO, Stulzer HK, Silva MAS, Matos JR. Physical-chemical characterization and polymorphism determination of two Nimodipine samples deriving from distinct laboratories. Drug Dev Ind Pharm. 2005;31:631–637. doi: 10.1080/03639040500216212. [DOI] [PubMed] [Google Scholar]
  • 13.Urbanetz NA, Lippold BH. Solid dispersions of nimodipine and polyethylene glycol 2000: dissolution properties and physico-chemical characterization. Eur J Pharm Biopharm. 2005;59:107–118. doi: 10.1016/j.ejpb.2004.08.005. [DOI] [PubMed] [Google Scholar]
  • 14.Verheyen S, Blaton N, Kinget R, Van den Mooter G. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm. 2002;249:45–58. doi: 10.1016/S0378-5173(02)00532-X. [DOI] [PubMed] [Google Scholar]
  • 15.Suzuki H, Sunada H. Some factors influencing the dissolution of solid dispersions with nicotinamide and hydroxypropylmethylcellulose as combined carriers. Chem Pharm Bull (Tokyo) 1998;46:1015–1020. doi: 10.1248/cpb.46.482. [DOI] [PubMed] [Google Scholar]
  • 16.Saers ES, Nystrom C, Alden M. Physicochemical aspects of drug release. XVI. The effect of storage on drug dissolution from solid dispersions and the influence of cooling rate and incorporation of surfactant. Int J Pharm. 1993;90:105–118. doi: 10.1016/0378-5173(93)90147-8. [DOI] [Google Scholar]
  • 17.Serajuddin ATM. Solid dispersion of poorly water soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88:1058–1066. doi: 10.1021/js980403l. [DOI] [PubMed] [Google Scholar]
  • 18.Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86:1–12. doi: 10.1021/js9601896. [DOI] [PubMed] [Google Scholar]
  • 19.Craig DQM. A review of thermal methods used for the analysis of the crystal form, solution thermodynamics and glass transition behaviour of polyethylene glycols. Thermochim Acta. 1995;248:189–203. doi: 10.1016/0040-6031(94)01886-L. [DOI] [Google Scholar]
  • 20.Junginger HE, Wedler M. Thermal stability of mefrusidepolynilpyrrolidone solid dispersions. Pharm Res. 1986;3:41–44. doi: 10.1023/A:1016320831469. [DOI] [PubMed] [Google Scholar]
  • 21.Taylor LS, Zografi G. The quantitative analysis of crystallinity using FT-Raman spectroscopy. Pharm Res. 1998;15:755–761. doi: 10.1023/A:1011979221685. [DOI] [PubMed] [Google Scholar]
  • 22.Chan KLA, Kazarian SG. FTIR spectroscopic imaging of dissolution of a solid dispersion of Nifedipine in poly(ethylene glycol) Mol Pharm. 2004;1:331–335. doi: 10.1021/mp049973m. [DOI] [PubMed] [Google Scholar]
  • 23.Breitenbach J, Schrof W, Neumann J. Confocal Raman-spectrosopy: analytical approach to solid dispersions and mapping of drugs. Pharm Res. 1999;16:1109–1113. doi: 10.1023/A:1018956304595. [DOI] [PubMed] [Google Scholar]
  • 24.Bikiaris D, Papageorgiou GZ, Stergiou A, et al. Physicochemical studies on solid dispersions of poorly water-soluble drugs: evaluation of capabilities and limitations of thermal analysis techniques. Thermochim Acta. 2005;439:58–67. doi: 10.1016/j.tca.2005.09.011. [DOI] [Google Scholar]
  • 25.Wang SD, Herbette LG, Rhodes DG. Structure of the calcium channel antagonist, nimodipine. Acta Crystallogr. 1989;C45:1748–1751. doi: 10.1107/s010827018900329x. [DOI] [PubMed] [Google Scholar]
  • 26.Hancock B, Christensen K, Shamblin SL. Estimating the critical molecular mobility temperature (TK) of amorphous pharmaceutics. Pharm Res. 1998;15:1649–1651. doi: 10.1023/A:1011983923386. [DOI] [PubMed] [Google Scholar]
  • 27.Hancock B, Shamblin SL. Molecural modility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim Acta. 2001;380:95–107. [Google Scholar]
  • 28.Vyazovkin S, Dranca I. Physical stability and relaxation of amorphous indomethacin. J Phys Chem B. 2005;109:18637–18644. doi: 10.1021/jp052985i. [DOI] [PubMed] [Google Scholar]
  • 29.Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995;12:799–806. doi: 10.1023/A:1016292416526. [DOI] [PubMed] [Google Scholar]
  • 30.Karavas E, Georgarakis E, Bikiaris D. Felodipine nanodispersions as active core for predictable pulsatile chronotherapeutics using PVP/ HPMC blends as coating layer. Int J Pharm. 2006;313:189–197. doi: 10.1016/j.ijpharm.2006.01.015. [DOI] [PubMed] [Google Scholar]
  • 31.Kanaze FI, Kokkalu E, Niopas I, Georgarakis E, Stergiou A, Bikiaris D. Dissolution enhancement of flavonoids by solid dispersion in PVP and PEG matrices. A comparative study. J Appl Polym Sci. 2006;102:460–471. doi: 10.1002/app.24200. [DOI] [Google Scholar]
  • 32.Karavas E, Ktistis G, Xenakis A, Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of Felodipine from nanodispersions with poly (vinyl pyrrolidone) Eur J Pharm Biopharm. 2006;63:103–114. doi: 10.1016/j.ejpb.2006.01.016. [DOI] [PubMed] [Google Scholar]
  • 33.Karavas E, Georgarakis E, Bikiaris D. Application of PVP/HPMC miscible blends with enhanced mucoadhesive properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm. 2006;64:115–116. doi: 10.1016/j.ejpb.2005.12.013. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES